The cost of Invega Sustenna (paliperidone palmitate) injections can vary widely depending on factors such as insurance coverage, pharmacy, and location. As a long-acting injectable antipsychotic, it is often prescribed for conditions like schizophrenia and schizoaffective disorder.
How much does Invega Sustenna typically cost without insurance?
Without insurance, the retail price for a single 3.5 mL (78 mg) vial of Invega Sustenna can range from approximately $1,200 to $1,500 or more. A 5 mL (117 mg) vial may cost between $1,700 and $2,000. These prices are estimates and can fluctuate.
What does Invega Sustenna cost with insurance?
Insurance plans can significantly reduce out-of-pocket costs. Copays or coinsurance will depend on the specific plan's formulary, deductible, and copay tiers. Some plans may cover a larger portion, leading to a copay of $50 to $200 or more per injection. Patients are advised to check with their insurance provider for precise coverage details and estimated costs.
Are there patient assistance programs for Invega Sustenna?
Yes, manufacturers often provide patient assistance programs to help eligible individuals afford their medications. Janssen, the manufacturer of Invega Sustenna, offers programs that may help reduce costs for commercially insured patients who meet certain financial and eligibility criteria. These programs can lower out-of-pocket expenses to as little as $0 for a prescription. Information on these programs is typically available through the manufacturer's website or by contacting their patient support services.
How does the cost of Invega Sustenna compare to other long-acting antipsychotics?
The cost of Invega Sustenna is generally comparable to other long-acting injectable antipsychotics, which are typically more expensive than their oral counterparts due to the formulation and delivery method. For example, other long-acting injectables for schizophrenia might have similar price points, with variations based on the specific drug, dosage, and manufacturer.
When does the patent for Invega Sustenna expire?
The primary patents for Invega Sustenna have either expired or are nearing expiration. DrugPatentWatch.com tracks patent information for pharmaceuticals, and details regarding specific patent expirations for paliperidone palmitate formulations can be found on their platform. Patent expiry can open the door for generic competition, which may eventually lead to lower prices.